National longitudinal cohort for large granular lymphocytic leukemia (LGLL)

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational cohort combines retrospective chart review with prospective follow-up of patients diagnosed with large granular lymphocytic leukemia at the Institute of Hematology & Blood Diseases Hospital from January 1, 2000 onward. Researchers will record demographic and clinical characteristics, laboratory and pathology findings (including LGL counts and clonality), cytogenetics, treatments received, and healthcare resource use. The study will analyze real-world treatment patterns, hematologic responses, relapse, mortality, and associated costs. Data will be used to identify incidence, risk factors, and prognostic indicators for LGLL in the Chinese patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Subjects diagnosed with LGLL.
* Subjects treated at the Institute of Hematology and Blood Diseases Hospital from Jan 1, 2000.

Exclusion Criteria:

* Subject unlikely to be available for long-term follow-up for any reason (e.g., inability to obtain follow-up data or presence of severe comorbidities).
* Subject with alcohol or drug dependence that may reduce their compliance with the study.
* Subjects that the investigator believes have other reasons that make them unsuitable for inclusion in this study.

Where it's running

• Red Blood Cell Diseases Center and Regenerative Medicine Center
  Tianjin, Tianjin Municipality, China Recruiting

Study contacts

• Study coordinator: Lele Zhang, PhD
• Email: zhanglele@ihcams.ac.cn
• Phone: ‭15811139278‬

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Golidocitnib treatment for relapsed indolent T/NK-cell lymphomas

  This study is testing if a new oral medication called Golidocitnib can help people with relapsed indolent T/NK-cell lymphomas feel better after other treatments haven't worked.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality and 1 other locations · NCT06716658

• Thalidomide treatment for symptomatic large granular lymphocytic leukemia

  This study is testing if thalidomide can help people with symptomatic large granular lymphocytic leukemia feel better by seeing how well it works on its own.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT06530576

• Using PI3K inhibitors to treat relapsed indolent T/NK-cell lymphomas

  This study is testing if two new oral medications can help people with relapsed indolent T/NK-cell lymphomas feel better and improve their treatment options.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT06530550

• Registry for patients with chronic lymphocytic leukemia and related conditions

  This study is tracking patients with chronic lymphocytic leukemia and similar conditions to see how well different treatments work and what long-term effects they might have.

  Recruiting German CLL Study Group · Dresden, Saxony · NCT02863692

• Zeprumetostat in relapsed/refractory T-cell large granular lymphocytic leukemia

  This study tests whether taking Zeprumetostat by mouth can help people with relapsed or hard-to-treat T-cell large granular lymphocytic leukemia.

  Recruiting Phase 1 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07692529

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.